BLX-028914(BLX-028914) - 药物靶点：PDE4_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

PDE4

作用机制

PDE4抑制剂(磷酸二酯酶4抑制剂)

治疗领域

免疫系统疾病感染耳鼻咽喉疾病+ [1]

在研适应症-

非在研适应症

过敏性鼻炎

原研机构

Orexo AB

在研机构-

非在研机构

Orexo ABDart NeuroScience LLC

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

2

项与 BLX-028914 相关的临床试验

NCT00758446 / Completed临床2期

A Double-blind, Randomized, Placebo-controlled, Cross-over, Allergen Challenge Study to Evaluate the Efficacy, Safety and Tolerability of BLX-028914 in Subjects With Allergic Rhinitis

This is a phase II study in patients with seasonal allergic rhinitis (SAR) and will compare the effect versus placebo of two different oral doses of BLX-028914 in an allergen challenge model. BLX-028914, a selective phosphodiesterase-4 (PDE4) inhibitor with a promising safety profile,is currently under development for treatment of airway diseases by Orexo AB, Sweden.
The aim of this study is to compare the effect, safety and tolerability of 14 days treatment with BLX-0289014 in patients with SAR in an allergen challenge model versus placebo.

开始日期2008-09-01

申办/合作机构

Dart NeuroScience LLC

[+1]

EUCTR2008-001179-30-SE / Not yet recruitingN/A

A double-blind, randomized, placebo-controlled, cross-over, allergen challenge study to evaluate the efficacy, safety and tolerability of BLX-028914 in subjects with allergic rhinitis

开始日期2008-06-30

申办/合作机构

Orexo AB

100 项与 BLX-028914 相关的临床结果

登录后查看更多信息

100 项与 BLX-028914 相关的转化医学

登录后查看更多信息

100 项与 BLX-028914 相关的专利（医药）

登录后查看更多信息

100 项与 BLX-028914 相关的药物交易

登录后查看更多信息